Abstract
e15732Background: nal-IRI is a nanoliposomal formulation of irinotecan. In the primary analysis of the pivotal NAPOLI-1 Phase-3 trial, nal-IRI+5-FU/LV significantly improved median overall survival...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have